FENC$10.563.13%0.32
After Hours: 10.54-0.02 -0.19%
Fennec Pharmaceuticals Inc (FENC)
Date: 2026-11-02 16:00O: 10.13H: 10.60L: 10.01C: 10.56Vol: 133.1k
Fennec Pharmaceuticals Inc stock is traded at $10.56, with a volume of 163,878. It is up +3.13% in the last 24 hours and up +3.53% over the past month. Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Previous Close:
$10.24
Open:
$10.13
24h Volume:
163,878
Relative Volume:
1.40
Market Cap:
$370.31M
Revenue:
$51.00M
Net Income/Loss:
-$8.73M
P/E Ratio:
-
EPS:
-$0.2962
Net Cash Flow:
-$7.75M
1W Performance:
+4.04%
1M Performance:
+3.53%
6M Performance:
+61.47%
1Y Performance:
+28.78%
1-Day Range:
$10.01$10.60
1-Week Range:
$10.05$11.25
52-Week Range:
$5.65$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(919) 636-4530Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC, USACompare FENC vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|
FENC Fennec Pharmaceuticals Inc | $370.31M | $59.22M | -$3.25M | -$7.75M | -$0.2962 |
 VRTX Vertex Pharmaceuticals Inc | $140.94B | $12.59B | $4.41B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $99.46B | $16.90B | $4.82B | $3.79B | $41.04 |
 MRNA Moderna Inc | $88.17B | $2.23B | -$3.15B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $55.03B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $40.86B | $6.13B | $655.71M | $1.10B | $4.48 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
- MARCO BRUGHERASep 15 '26Director
- Transaction
- Proposed Sale
- Cost
- $10.30
- #Shares
- 15,545
- Value ($)
- 160,070
- #Shares Total
- 0
- Brughera Marco MariaSep 15 '26Director
- Transaction
- Sale
- Cost
- $10.29
- #Shares
- 15,545
- Value ($)
- 159,958
- #Shares Total
- 0
- ROSTISLAV RAYKOVSep 01 '26Former Director
- Transaction
- Proposed Sale
- Cost
- $12.12
- #Shares
- 10,000
- Value ($)
- 121,177
- #Shares Total
- 0
- Raykov RostySep 01 '26Former Director
- Transaction
- Sale
- Cost
- $12.11
- #Shares
- 10,000
- Value ($)
- 121,100
- #Shares Total
- 124,411
- PIERRE S SAYADAug 31 '26Officer
- Transaction
- Proposed Sale
- Cost
- $12.18
- #Shares
- 12,000
- Value ($)
- 146,170
- #Shares Total
- 0
- Sayad Pierre SargisAug 31 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $12.18
- #Shares
- 12,000
- Value ($)
- 146,160
- #Shares Total
- 9,519
- Andrade RobertAug 28 '26CHIEF FINANCIAL OFFICER
- Transaction
- Option Exercise
- Cost
- $5.10
- #Shares
- 21,928
- Value ($)
- 111,833
- #Shares Total
- 239,603
- ROBERT ANDRADEAug 27 '26Officer
- Transaction
- Proposed Sale
- Cost
- $11.79
- #Shares
- 75,000
- Value ($)
- 883,898
- #Shares Total
- 0
- Andrade RobertAug 27 '26CHIEF FINANCIAL OFFICER
- Transaction
- Sale
- Cost
- $11.78
- #Shares
- 75,000
- Value ($)
- 883,500
- #Shares Total
- 217,675
- ROSTISLAV RAYKOVAug 03 '26Former Director
- Transaction
- Proposed Sale
- Cost
- $9.58
- #Shares
- 10,000
- Value ($)
- 95,835
- #Shares Total
- 0
